| scholarly article | Q13442814 |
| P50 | author | Apriliana Cahya Khayrani | Q52729698 |
| Akimasa Seno | Q52729719 | ||
| Ayano Satoh | Q59682873 | ||
| Tsukasa Shigehiro | Q59694720 | ||
| Masaharu Seno | Q42407066 | ||
| P2093 | author name string | Tetsuya Ito | |
| Hiroshi Murakami | |||
| Akifumi Mizutani | |||
| Junko Masuda | |||
| Tomonari Kasai | |||
| Hiroki Hamada | |||
| Arun Vaidyanath | |||
| Tadakatsu Mandai | |||
| Shoki Saito | |||
| Yuhki Seno | |||
| Kazumasa Jinno | |||
| P2860 | cites work | Efficient drug delivery of Paclitaxel glycoside: a novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation | Q28543361 |
| Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation | Q33182379 | ||
| Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells | Q33205615 | ||
| Liposomal Formulations in Clinical Use: An Updated Review. | Q33850427 | ||
| Novel formulations of taxanes: a review. Old wine in a new bottle? | Q34563540 | ||
| A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect | Q34730580 | ||
| Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel | Q35851121 | ||
| Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. | Q36062352 | ||
| Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. | Q36983366 | ||
| Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes | Q37267205 | ||
| Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand | Q37294882 | ||
| Nanoparticles evading the reticuloendothelial system: role of the supported bilayer | Q37376443 | ||
| Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects | Q37792340 | ||
| Doxil®--the first FDA-approved nano-drug: lessons learned | Q38000876 | ||
| Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes | Q56386325 | ||
| Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures | Q71561921 | ||
| Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere) | Q71585369 | ||
| Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases | Q72927459 | ||
| Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes | Q73367835 | ||
| Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel | Q73734066 | ||
| Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients | Q77521323 | ||
| Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes | Q86702329 | ||
| Liposomal paclitaxel formulations | Q38044520 | ||
| Evaluation of glycosylated docetaxel-encapsulated liposomes prepared by remote loading under solubility gradient | Q38793511 | ||
| Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages | Q38928086 | ||
| Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours | Q39001270 | ||
| Cancer nanomedicine: progress, challenges and opportunities | Q39005226 | ||
| Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts | Q39627234 | ||
| Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. | Q39730835 | ||
| Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect | Q39776258 | ||
| Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage | Q39866499 | ||
| Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells | Q40082780 | ||
| Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines | Q40106465 | ||
| Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome | Q40116440 | ||
| Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation | Q40157398 | ||
| Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells | Q40446727 | ||
| The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). | Q40713819 | ||
| Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice | Q41090683 | ||
| Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma | Q43869754 | ||
| Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel | Q44558863 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P577 | publication date | 2017-09-23 | |
| P1433 | published in | Nanomaterials | Q27724944 |
| P1476 | title | Practical Liposomal Formulation for Taxanes with Polyethoxylated Castor Oil and Ethanol with Complete Encapsulation Efficiency and High Loading Efficiency | |
| P478 | volume | 7 |
Search more.